BioMarin Acquires Amicus Therapeutics for $4.8 Billion After Resolving Patent Litigation

By Editorial Team

BioMarin Pharmaceutical Inc. has announced the acquisition of Amicus Therapeutics for $4.8 billion. The deal comes after Amicus settled patent litigation, ensuring exclusive rights for its Galafold drug in the United States until 2037.

The agreement marks a significant milestone for both companies, with BioMarin expanding its portfolio through the acquisition of Amicus. The resolution of the patent dispute secures a clear path for Amicus to continue developing and marketing Galafold without competition in the U.S. market for the next 16 years.

With this acquisition, BioMarin aims to strengthen its position in the pharmaceutical industry and enhance its offerings to patients in need of innovative treatment options. The deal underscores BioMarin’s commitment to growth and innovation in the life sciences sector.

Both companies have expressed optimism about the future prospects of their collaboration and the potential benefits it will bring to patients, shareholders, and the broader healthcare community. The acquisition is subject to regulatory approvals and other customary closing conditions.

For more legal news and updates, subscribe to Law360 for comprehensive coverage of the latest developments in the legal and business world.